Options vested and expected to vest, ending Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Adjustments to reconcile net loss to net cash provided by (used in) operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Statistical Measurement Statistical Measurement [Domain] Prepaid expenses Increase (Decrease) in Prepaid Expense Assets under construction Asset under Construction [Member] Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] Microchips Biotech, Inc. Microchips Biotech, Inc. [Member] Microchips Biotech, Inc. [Member] Cover [Abstract] Weighted Average Remaining Life in Years Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract] Net change in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Future Minimum Lease Payment Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Income Tax Jurisdiction Income Tax Jurisdiction [Domain] Going Concern Liquidity [Policy Text Block] Liquidity Trading Symbol Trading Symbol Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] All Trading Arrangements All Trading Arrangements [Member] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Other indirect costs Other Indirect Costs [Member] Other Indirect Costs Non-NEOs Non-NEOs [Member] Vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Research credit carryforwards Tax Credit Carryforward, Amount Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Sale Of Future Royalties Sale Of Future Royalties [Member] Sale Of Future Royalties Accrued clinical expense Accrued Clinical Expense, Current Accrued Clinical Expense, Current Square feet of office space Net Rentable Area Pay vs Performance Disclosure [Line Items] License And Collaboration Agreement License And Collaboration Agreement [Member] License And Collaboration Agreement [Member] Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Amended and Restated 2014 Stock Incentive Plan Amended And Restated Two Thousand Fourteen Stock Incentive Plan [Member] Amended And Restated Two Thousand Fourteen Stock Incentive Plan [Member] Milestone payments, contingent amount Milestone Payments, Contingent Amount Milestone payments, contingent amount. Weighted- Average Remaining Contractual Life (Years) Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term Roll Forward Share based compensation arrangement by share based payment award options outstanding weighted average remaining contractual term roll forward. Net Loss Per Share Earnings Per Share, Policy [Policy Text Block] Organization and Description of Business Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Operating lease liability Increase (Decrease) in Operating Lease Liability Options exercisable, ending (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding And Exercisable, Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding And Exercisable, Weighted Average Grant Date Fair Value Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Issuance of common stock from the exercise of warrants (in shares) Issuance Of Common Stock From Exercise Of Warrants, Shares Issuance Of Common Stock From Exercise Of Warrants, Shares Award Timing Disclosures [Line Items] Pear Tree Pharmaceuticals, Inc. Pear Tree Pharmaceuticals, Inc. [Member] Pear Tree Pharmaceuticals, Inc. Other Performance Measure, Amount Other Performance Measure, Amount Research Credit Carryforwards Research Tax Credit Carryforward [Member] Portion at Fair Value Measurement Portion at Fair Value Measurement [Member] Leased Properties Lessee, Operating Leases [Text Block] Common stock, shares outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding Documents Incorporated by Reference Documents Incorporated by Reference [Text Block] Non-cash lease expenses Operating Lease, Cost Other receivables Other Receivables, Net, Current Interest payable Increase (Decrease) in Interest Payable, Net Prepaid development expense Prepaid Development Expense, Current Prepaid Development Expense, Current Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] March 2023 At The Market Sales Agreement March 2023 At The Market Sales Agreement [Member] March 2023 At The Market Sales Agreement Lease liabilities, non-current Operating Lease, Liability, Noncurrent Cash flows from financing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Segment Information Segment Reporting, Policy [Policy Text Block] Warrant term Warrants and Rights Outstanding, Term Plan Name [Domain] Plan Name [Domain] Other non-current assets Other Assets, Noncurrent Entity Tax Identification Number Entity Tax Identification Number Leases [Abstract] Leases [Abstract] Contra R&D expenses Contra Research And Development Expense, Indirect Costs Contra Research And Development Expense, Indirect Costs Research and development credit carryforwards Deferred Tax Assets, Tax Credit Carryforwards, Research Grant, DARE-PTB1 Grant, DARE-PTB1 [Member] Grant, DARE-PTB1 Interest rate on insurance financing Insurance Financing, Interest Rate Insurance Financing, Interest Rate Net cash provided by (used in) operating activities Net Cash Provided by (Used in) Operating Activities Net proceeds from sale of stock offering Sale of Stock, Consideration Received on Transaction Project [Domain] Project [Domain] Other operating expenses Other Cost and Expense, Operating Plan Name [Axis] Plan Name [Axis] Reverse stock split adjustment Stock Issued During Period, Value, Reverse Stock Splits Stock Issued During Period, Value, Reverse Stock Splits Prepaid expenses Total prepaid expenses Prepaid Expense, Current Equity Components Equity Components [Axis] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Award Timing Method Award Timing Method [Text Block] Research and Development Costs Research and Development Expense, Policy [Policy Text Block] Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Measurement Frequency [Axis] Measurement Frequency [Axis] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Insider Trading Policies and Procedures [Line Items] Total obligation License And Services Agreement, Total Obligation License And Services Agreement, Total Obligation Use of Estimates Use of Estimates, Policy [Policy Text Block] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Adjustment to Compensation, Amount Adjustment to Compensation Amount Outstanding, ending Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Additional paid-in capital Additional Paid in Capital, Common Stock Payables and Accruals [Abstract] Payables and Accruals [Abstract] Compensation Amount Outstanding Recovery Compensation Amount Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Entity Small Business Entity Small Business Accrued Expenses Accounts Payable and Accrued Liabilities Disclosure [Text Block] Company Selected Measure Amount Company Selected Measure Amount Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract] Amount awarded for grant Proceeds From Award Of Grants Proceeds From Award Of Grants Issuance costs Payments of Debt Issuance Costs Tabular List, Table Tabular List [Table Text Block] Deferred tax assets, increase in valuation allowance Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Level 3 Fair Value, Inputs, Level 3 [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Research and development funding percentage Research and Development Arrangement with Federal Government, Customer Funding to Offset Costs Incurred, For General And Administrative Expenses, Percentage Research and Development Arrangement with Federal Government, Customer Funding to Offset Costs Incurred, For General And Administrative Expenses, Percentage Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Accrued expenses Accrued Liabilities, Current Proceeds from royalties received Upfront payment from the sale of future royalties Proceeds from Royalties Received Class of Warrant or Right [Line Items] Class of Warrant or Right [Line Items] License and services agreement term License And Services Agreement, Term License And Services Agreement, Term Cash, cash equivalents and restricted cash, beginning of year Cash, cash equivalents and restricted cash, end of year Total cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Accounts and Financing Receivables [Table] July 2023 Financing July 2023 Financing [Member] July 2023 Financing Royalty Interest Financing Royalty Interest Financing [Text Block] Royalty Interest Financing Current Assets Assets, Current [Abstract] Payment to be received upon termination without cause Employment Agreement, Salary Payment Received Upon Termination Without Cause Employment Agreement, Salary Payment Received Upon Termination Without Cause Fair Value of Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Sales Milestones Sales Milestones [Member] Sales Milestones [Member] Payment to be received upon termination for cause or for good reason Employment Agreement, Salary Payment Received Upon Termination for Cause or Good Reason Employment Agreement, Salary Payment Received Upon Termination for Cause or Good Reason Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Issuance cost recorded under additional-paid-in-capital Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction National Collegiate Inventors And Innovators Alliance, Inc. d/b/a VentureWell National Collegiate Inventors And Innovators Alliance, Inc. d/b/a VentureWell [Member] National Collegiate Inventors And Innovators Alliance, Inc. d/b/a VentureWell Total payment Research and Development Agreement, Commitment, Amount Research and Development Agreement, Commitment, Amount Product and Service [Domain] Product and Service [Domain] Stock Options Share-Based Payment Arrangement, Option [Member] Net proceeds from issuance of common stock Net Proceeds From Issuance Of Common Stock And Warrants Net Proceeds From Issuance Of Common Stock And Warrants Depreciation expense Depreciation 2025 Lessee, Operating Lease, Liability, to be Paid, Year One License fee revenue License [Member] Additional investment amount Class Of Warrant Or Right, Supplement Investment Class Of Warrant Or Right, Supplement Investment Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Outstanding and exercisable, Weighed Average Remaining Life in Years Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding And Exercisable, Weighted Average Remaining Contractual Terms Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding And Exercisable, Weighted Average Remaining Contractual Terms Total research and development direct program costs Research And Development Expense, Direct Program Costs, Net Research And Development Expense, Direct Program Costs, Net Upon Achieving Certain Commercial Milestones Upon Achieving Certain Commercial Milestones [Member] Upon Achieving Certain Commercial Milestones [Member] Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Warrant Warrant [Member] Other receivables Increase (Decrease) in Other Receivables Foundation Foundation [Member] Foundation Biotherapeutic Product Grant Agreement Biotherapeutic Product Grant Agreement [Member] Biotherapeutic Product Grant Agreement Class of warrant or right, extent holder own percentage Class of Warrant or Right, Extent Holder Own Percentage Class of Warrant or Right, Extent Holder Own Percentage Number of significant performance obligations Revenue, Number Of Significant Performance Obligations Revenue, Number Of Significant Performance Obligations Award Type [Axis] Award Type [Axis] Related Party Transaction Related Party Transaction [Domain] Basis after conversion (in shares) Stockholders' Equity Note, Stock Split, Conversion Basis After Reverse Stock Split Stockholders' Equity Note, Stock Split, Conversion Basis After Reverse Stock Split Aggregate commission rate Percentage Of Aggregate Commission Percentage of aggregate commission. Proceeds from the sale of future royalties, net Proceeds From Sale Of Future Royalties, Net Proceeds From Sale Of Future Royalties, Net Granted Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Cash, Cash Equivalents and Restricted Cash Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag Total liabilities Liabilities Class of warrant or right, exercises Class Of Warrant Or Right, Exercises Class Of Warrant Or Right, Exercises Accrued development expense Accrued Development Expense, Current Accrued Development Expense, Current CRADA CRADA [Member] CRADA Options exercisable, ending (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Common stock, par value (in usd per share) Common Stock, Par or Stated Value Per Share Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Research and development Research and Development Expense Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Lab equipment Lab Equipment [Member] Lab Equipment Expiration Date Trading Arrangement Expiration Date Number of Shares Underlying Warrants Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward] Cash flow from operations Net Cash Provided by (Used in) Operating Activities, Continuing Operations Royalty Purchase Agreement Royalty Purchase Agreement [Member] Royalty Purchase Agreement Class of warrant or right, number of securities called by each warrant or right Class of Warrant or Right, Number of Securities Called by Each Warrant or Right Current portion of lease liabilities Operating Lease, Liability, Current Total Shareholder Return Amount Total Shareholder Return Amount Common stock, shares issued (in shares) Common Stock, Shares, Issued Upon Achieving Certain Clinical And Regulatory Development Milestones Upon Achieving Certain Clinical And Regulatory Development Milestones [Member] Upon Achieving Certain Clinical And Regulatory Development Milestones [Member] Entity [Domain] Entity [Domain] Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Concentration risk percentage Concentration Risk, Percentage Initial payment Grants Receivable Authorized amount (up to) Sale Of Stock, Authorized, Amount Sale Of Stock, Authorized, Amount Net operating loss carryforwards Deferred Tax Assets, Operating Loss Carryforwards Other cost Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross Number of additional payment Royalty Agreement, Number Of Additional Payments Royalty Agreement, Number Of Additional Payments Class of warrant or right, extent holder own percentage Class of Warrant or Right, Holder Election Percentage Class of Warrant or Right, Holder Election Percentage Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Less– accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Proceeds from sale of royalty and milestone rights Proceeds From Sale Of Royalty And Milestone Rights Proceeds From Sale Of Royalty And Milestone Rights Property and equipment, gross Property, Plant and Equipment, Gross Prepaid insurance expense Prepaid Insurance Sales based milestones amount Milestone Payments, Contingent Amount, Sales Based Milestones Amount Milestone Payments, Contingent Amount, Sales Based Milestones Amount Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Advanced written notice period Upfront License Fee, Advanced Written Notice, Period Upfront License Fee, Advanced Written Notice, Period Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Research and development Research and Development Expense [Member] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Class of Warrant or Right [Table] Class of Warrant or Right [Table] Personnel-related (including stock compensation) Personnel-Related (Including Stock Compensation) [Member] Personnel-Related (Including Stock Compensation) Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Bayer Bayer Healthcare LLC [Member] Bayer Healthcare LLC Transaction costs Sale Of Royalty And Milestone Rights, Net Of Transaction Costs Sale Of Royalty And Milestone Rights, Net Of Transaction Costs MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Bayer Healthcare License Agreement Bayer Healthcare License Agreement [Member] Bayer Healthcare License Agreement [Member] Exercisable (in shares) Share-Based Compensation Arrangement By Share-Based Payment Award, Non-Option Equity Instruments, Outstanding And Exercisable Share-Based Compensation Arrangement By Share-Based Payment Award, Non-Option Equity Instruments, Outstanding And Exercisable Total stockholders' deficit Beginning balance Ending balance Equity, Attributable to Parent Total deferred tax assets Deferred Tax Assets, Gross Entity Voluntary Filers Entity Voluntary Filers Strategic Agreements Collaborative Arrangement Disclosure [Text Block] Related Party Related Party [Member] Renewal term of operating lease Lessee, Operating Lease, Renewal Term Cash flows from investing activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Interest expense Interest Expense, Nonoperating Health insurance premium Health Insurance Premiums, Monthly Amount Health Insurance Premiums, Monthly Amount Property and Equipment, Net Property, Plant and Equipment Disclosure [Text Block] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Fair Value, Measurements, Recurring Fair Value, Recurring [Member] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Options to purchase number of outstanding shares of common stock (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Sale of Stock [Domain] Sale of Stock [Domain] Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Document Fiscal Period Focus Document Fiscal Period Focus All Executive Categories All Executive Categories [Member] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Outstanding, ending Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Assets Assets [Abstract] Dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Outstanding beginning balance (in shares) Outstanding ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number Other development programs Other Development Programs [Member] Other Development Programs Research and development expense credit Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount Document Type Document Type Accrued indemnification provisions Accrued Indemnification Provisions Accrued indemnification provisions. Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Measurement Input, Expected Dividend Payment Measurement Input, Expected Dividend Payment [Member] Schedule of Segment Reporting Information, by Segment Schedule of Segment Reporting Information, by Segment [Table Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Non-dilutive grant funding, percentage excluded Non-Dilutive Grant Funding, Percentage Excluded Non-Dilutive Grant Funding, Percentage Excluded Issuance cost on equity line paid in common stock (in shares) Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs, Shares Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs, Shares Document Annual Report Document Annual Report Non-cash interest expense on liability related to sale of future royalties Non-Cash Interest Expense On Liability Related To Sale Of Future Royalties Non-Cash Interest Expense On Liability Related To Sale Of Future Royalties Option exercisable, ending Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Other income (expense) Other Income and Expenses [Abstract] Former Stockholders of MBI Former Stockholders of MBI [Member] Former Stockholders of MBI Other advanced clinical stage programs Other Advanced Clinical Stage Programs [Member] Other Advanced Clinical Stage Programs Sildenafil Cream, 2.0% Sildenafil Cream, 2.0% [Member] Sildenafil Cream, 2.0% Basis prior to conversion (in shares) Stockholders' Equity Note, Stock Split, Conversion Basis Prior To Reverse Stock Split Stockholders' Equity Note, Stock Split, Conversion Basis Prior To Reverse Stock Split Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Commitments And Contingencies [Table] Commitments And Contingencies [Table] Commitments and contingencies. Research and Development Arrangement, Contract to Perform for Others, Type Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Maximum Maximum [Member] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Merger Agreement Merger Agreement [Member] Merger Agreement Project [Axis] Project [Axis] Premiums, taxes and fees Insurance Financing, Premiums, Taxes And Fees, Amount Insurance Financing, Premiums, Taxes And Fees, Amount Accounts payable Accounts Payable, Current Accounting Policies [Abstract] Accounting Policies [Abstract] Revenue Revenue: Revenues [Abstract] DARE-HPV DARE-HPV [Member] DARE-HPV Sale of royalty and milestone rights, net of transaction costs (Note 13) Sale of royalty and milestone rights, net Royalty Income, Nonoperating Shares issued, price per share Shares Issued, Price Per Share Leasehold improvements Leasehold Improvements [Member] Indemnification Obligations Guarantees, Indemnifications and Warranties Policies [Policy Text Block] Expired (in usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Number of experts License Agreement, Number Of Experts License Agreement, Number Of Experts Summary of Assumptions Used in Black-Scholes Option-Pricing Model for Stock Options Granted to Employees, and Non-Employee Directors Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Current Fiscal Year End Date Current Fiscal Year End Date Less: accreted interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Statistical Measurement Statistical Measurement [Axis] PEO Name PEO Name Commitments And Contingencies [Line Items] Commitments And Contingencies [Line Items] Commitments and contingencies. Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Loss before taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Equity Award [Domain] Award Type [Domain] Future net sales Royalty Agreement, Future Net Sales, Percentage Royalty Agreement, Future Net Sales, Percentage Name Outstanding Recovery, Individual Name Research and development: Research and Development Expense [Abstract] Licensing Agreements Licensing Agreements [Member] Stock compensation Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost Expiration period License Agreement, Expiration Period License Agreement, Expiration Period Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Royalty Purchase Agreements Royalty Purchase Agreements [Text Block] Royalty Purchase Agreements Supplier Concentration Risk Supplier Concentration Risk [Member] Non-PEO NEO Non-PEO NEO [Member] Unamortized stock-based compensation expense Deferred Compensation Share-Based Arrangements, Liability, Current and Noncurrent Additional Paid-in Capital Additional Paid-in Capital [Member] Major Vendor Major Vendor [Member] Major Vendor Award Timing Predetermined Award Timing Predetermined [Flag] Reimburse amount, PDUFA fees and other manufacturing expenses Milestone Payments, Reimburse Amount, PDUFA Fees and Other Manufacturing Expenses Milestone Payments, Reimburse Amount, PDUFA Fees and Other Manufacturing Expenses Repayment of liability on sale of future royalties Repayment Of Liability On Sale Future Royalties Repayment Of Liability On Sale Future Royalties Collaborative Arrangement Collaborative Arrangement [Member] Class of Stock [Line Items] Class of Stock [Line Items] Vendor Concentration Concentration Risk Disclosure [Text Block] Recently Adopted Accounting Pronouncements/Recently Issued Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Loss per common share - diluted (in usd per share) Earnings Per Share, Diluted Counterparty Name [Domain] Counterparty Name [Domain] Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Supplemental investment (in shares) Class Of Warrant Or Right, Supplement Investment Share Amount Class Of Warrant Or Right, Supplement Investment Share Amount Name Measure Name 2014 Employee Stock Purchase Plan Two Thousand And Fourteen Employee Stock Purchase Plan [Member] Two thousand and fourteen employee stock purchase plan. State State and Local Jurisdiction [Member] Domestic Income (Loss) from Continuing Operations before Income Taxes, Domestic Entity Interactive Data Current Entity Interactive Data Current Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Schedule of Warrant Activity Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Number of operating segments Number of Operating Segments Defined contribution plan, employer matching contribution, percent of match Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay Insurance Financing Insurance Financing [Member] Insurance Financing XOMA XOMA (US) LLC [Member] XOMA (US) LLC Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Performance period Research And Development Arrangement, Performance Period Research And Development Arrangement, Performance Period Customer [Axis] Customer [Axis] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Amortized weighted average period Weighted Average Amortization Period Weighted Average Amortization Period Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Net deferred tax assets Deferred Tax Assets, Net of Valuation Allowance Accrued license fee expense Accrued License Expense, Current Accrued License Expense, Current Contingent Consideration Type [Domain] Contingent Consideration Type [Domain] Income tax provision Income Tax Expense (Benefit) Health coverage to be received upon termination without cause Employment Agreement, Health Benefits Coverage Received Upon Termination Without Cause Employment Agreement, Health Benefits Coverage Received Upon Termination Without Cause Issuance of common stock warrants, net of issuance costs Adjustments to Additional Paid in Capital, Warrant Issued Liability related to the sale of future royalties, net Royalty Guarantees, Commitments, Amount Direct program costs: Research And Development Direct Program Costs [Abstract] Research And Development Direct Program Costs Change in control of company, termination without cause or resignation for good reason, period Employment Agreement, Change In Control Of Company, Termination Without Cause Or Resignation For Good Reason Employment Agreement, Change In Control Of Company, Termination Without Cause Or Resignation For Good Reason, Period Supplemental disclosure of non-cash investing and financing activities: Supplemental Cash Flow Information [Abstract] Total revenue Revenue from Contract with Customer, Excluding Assessed Tax Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Vendor Two Major Vendor Two [Member] Major Vendor Two Maximum royalty payments Royalty Agreement, Maximum Royalty Payments Royalty Agreement, Maximum Royalty Payments Auditor Firm ID Auditor Firm ID Effective income tax rate Effective Income Tax Rate Reconciliation, Percent Milestone payments Research And Development, Milestone Payment Research and development milestone payment. Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Loss from operations Loss from operations Operating Income (Loss) Income Tax Jurisdiction Income Tax Jurisdiction [Axis] Stock compensation Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent Number of reportable segments Number of Reportable Segments Total liabilities and stockholders' deficit Liabilities and Equity Capitalized research and development costs Deferred Tax Assets Capitalized Research And Development Cost Deferred Tax Assets Capitalized Research And Development Cost Deferred grant funding Deferred Grant Funding, Current Deferred Grant Funding, Current Subsequent Events Subsequent Events [Text Block] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] All Adjustments to Compensation All Adjustments to Compensation [Member] Indirect costs: Research And Development Expense, Indirect Costs Research And Development Expense, Indirect Costs Accrued compensation and benefits Employee-related Liabilities, Current Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Significant Accounting Policies [Line Items] Significant Accounting Policies [Line Items] Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Period of insufficient cash and liquidity requirements Period of Insufficient Cash and Liquidity Requirements Period of Insufficient Cash and Liquidity Requirements Tax Credit Carryforward Tax Credit Carryforward [Axis] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Interest income Investment Income, Interest Legal Entity [Axis] Legal Entity [Axis] Operating right-of-use assets obtained in exchange for new operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Issuance of note payable Proceeds from Notes Payable Underlying Security Market Price Change Underlying Security Market Price Change, Percent Measurement Input Type [Axis] Measurement Input Type [Axis] Tax Credit Carryforward, Name Tax Credit Carryforward, Name [Domain] Individual: Individual [Axis] Related Party Transaction Related Party Transaction [Axis] Assignment Agreement Assignment Agreement [Member] Assignment Agreement [Member] Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] Schedule of Changes in the Liability Related to the Royalty Interest Financing Schedule Of Changes In The Liability Related To The Royalty Interest Financing [Table Text Block] Schedule Of Changes In The Liability Related To The Royalty Interest Financing Forfeited (in usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Prepaid legal and professional expenses Prepaid Professional Expense, Current Prepaid Professional Expense, Current Expected life in years Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Product and Service [Axis] Product and Service [Axis] Entity Address, State or Province Entity Address, State or Province Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Statement [Line Items] Statement [Line Items] Measurement Input Type [Domain] Measurement Input Type [Domain] Deposits Increase (Decrease) in Deposit Assets Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Significant Accounting Policies [Table] Significant Accounting Policies [Table] Significant accounting policies. License fee expense License Fee Expense License Fee Expense Operating expenses Segment operating expenses: Operating Expenses [Abstract] Schedule of Property and Equipment, Net Property, Plant and Equipment [Table Text Block] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Receivable for expenses eligible for reimbursement Receivable For Expenses Eligible For Reimbursement Receivable For Expenses Eligible For Reimbursement Accounts, Notes, Loans and Financing Receivable [Line Items] Accounts, Notes, Loans and Financing Receivable [Line Items] Outstanding beginning balance (in usd per share) Outstanding ending balance (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Liabilities and stockholders’ deficit Liabilities and Equity [Abstract] Preclinical stage programs Preclinical Stage Programs [Member] Preclinical Stage Programs Change in valuation allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent Risks and Uncertainties [Abstract] Minimum Minimum [Member] Restatement Determination Date Restatement Determination Date Options vested and expected to vest, ending (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Estimate of Fair Value Measurement Estimate of Fair Value Measurement [Member] Royalty revenue Royalty [Member] Adoption Date Trading Arrangement Adoption Date Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Warrants and rights outstanding, measurement input Warrants and Rights Outstanding, Measurement Input Related Party Transactions [Abstract] Deferred revenue, non-current Contract with Customer, Liability, Noncurrent Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Outstanding beginning balance (in usd per share) Outstanding ending balance (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Sildenafil Cream, 3.6% Sildenafil Cream, 3.6% [Member] Sildenafil Cream, 3.6% Concentration Risk [Table] Concentration Risk [Table] Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Stock options outstanding (in shares) Outstanding beginning balance (in shares) Outstanding ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Quarterly payment period Royalty Agreement, Quarterly Payments, Period Royalty Agreement, Quarterly Payments, Period Health coverage to be received upon termination for cause or for good reason Employment Agreement, Health Benefits Coverage Received Upon Termination for Cause or Good Reason Employment Agreement, Health Benefits Coverage Received Upon Termination for Cause or Good Reason Segments [Axis] Segments [Axis] Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] DARE-LARC1 DARE-LARC1 [Member] DARE-LARC1 Clinical And Regulatory Milestones Clinical And Regulatory Milestones [Member] Clinical And Regulatory Milestones [Member] Federal statutory rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Property, Plant and Equipment [Abstract] Exercise Price Award Exercise Price Exercise of Options Outstanding Exercise Of Options Outstanding [Member] Exercise of options outstanding. Summary of Major Components of Company's Deferred Tax Assets Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Arrangement Duration Trading Arrangement Duration Net operating loss carryforwards Operating Loss Carryforwards Research and development credit Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent Operating lease, incremental borrowing rate, prime rate Operating Lease, Incremental Borrowing Rate, Prime Rate Operating Lease, Incremental Borrowing Rate, Prime Rate Stockholders' deficit Equity, Attributable to Parent [Abstract] Granted (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Internal rate of return Royalty Agreement, Internal Rate Of Return Royalty Agreement, Internal Rate Of Return Federal Domestic Tax Jurisdiction [Member] Income Taxes Income Tax, Policy [Policy Text Block] Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Segments [Domain] Segments [Domain] Upon Reaching Certain Worldwide Net Sales Milestones Upon Reaching Certain Worldwide Net Sales Milestones [Member] Upon reaching certain worldwide net sales milestones. Right of use asset - operating lease Increase (Decrease) In Operating Lease Right-of-Use Asset Increase (Decrease) In Operating Lease Right-of-Use Asset Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Unrecognized Tax Benefits [Roll Forward] Unrecognized Tax Benefits [Roll Forward] All Individuals All Individuals [Member] United United in Endeavor, LLC [Member] United in Endeavor, LLC Commitments and Contingencies Commitments Disclosure [Text Block] PEO PEO [Member] Upon Achieving Certain Development Milestones Upon Achieving Certain Development Milestones [Member] Upon Achieving Certain Development Milestones [Member] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Name Trading Arrangement, Individual Name Other (expense) income Other Nonoperating Income (Expense) Outstanding and exercisable, Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding And Exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding And Exercisable Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Registered Direct Offering Registered Direct Offering [Member] Registered Direct Offering Consulting Agreement Consulting Agreement [Member] Consulting Agreement Receivables [Abstract] Receivables [Abstract] Contra-R&D expenses Contra Research And Development Expense, Direct Program Costs Contra Research And Development Expense, Direct Program Costs Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted Maximum potential milestone payments Maximum Potential Milestone Payments Maximum Potential Milestone Payments Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Entity Public Float Entity Public Float Other non-current assets Increase (Decrease) in Other Noncurrent Assets Percentage of royalty rate Royalty Rate, Percentage Percentage of royalty rate. Proceeds from the exercise of common stock warrants Proceeds From Issuance Of Common Stock And Warrants Proceeds from issuance of common stock and warrants. Phase II Segment Phase II Segment [Member] Phase II Segment MBI MBI [Member] MBI Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Other Commitments [Domain] Other Commitments [Domain] Catalent and MilanaPharm Catalent and MilanaPharm [Member] Catalent and MilanaPharm Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Measurement Input, Price Volatility Measurement Input, Price Volatility [Member] Common stock reserved for issuance (in shares) Common stock reserved for future issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Potential annual license maintenance fee payments, thereafter Potential Annual License Maintenance Fee Payments, Thereafter Potential Annual License Maintenance Fee Payments, Thereafter Related Party [Domain] Related and Nonrelated Parties [Domain] Operating loss carryforwards not subject to expiration Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Total accrued expenses Accounts Payable and Accrued Liabilities, Current Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Local Phone Number Local Phone Number Valuation allowance Deferred tax valuation allowance Deferred Tax Assets, Valuation Allowance Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Insurance financing payable Insurance Financing Payable Insurance Financing Payable Total operating expenses Operating Expenses Prepaid Expenses Other Current Assets [Text Block] Expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Maximum percentage increase License And Services Agreement, Maximum Fee Increase, Percentage License And Services Agreement, Maximum Fee Increase, Percentage Milestone payment revenues Milestone Payment Revenues Milestone Payment Revenues Working capital deficit Working Capital (Deficit) Working Capital (Deficit) Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] PEO Total Compensation Amount PEO Total Compensation Amount Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Potential future payment Royalty Agreement, Maximum Potential Milestone Payments Royalty Agreement, Maximum Potential Milestone Payments Statement of Income Location, Balance [Axis] Statement of Income Location, Balance [Axis] Cash balance of financial institutions insured by federal deposits insurance corporation Cash, FDIC Insured Amount Options vested and expected to vest, ending (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Licensed Product or Process for Vaginal or Urological Use Licensed Product or Process for Vaginal or Urological Use [Member] Licensed Product or Process for Vaginal or Urological Use Vendor One Major Vendor One [Member] Major Vendor One Common stock Common Stock [Member] Measure: Measure [Axis] Sale of stock, prospectus offering amount Sale Of Stock, Prospectus Offering Amount Sale Of Stock, Prospectus Offering Amount Impairment of Long-Lived Assets Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block] Current year - increases Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Table] Outstanding, Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding Stock split, conversion ratio Stockholders' Equity Note, Stock Split, Conversion Ratio Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Issuance of common stock, net of issuance costs (in shares) Stock Issued During Period, Shares, New Issues Entity Emerging Growth Company Entity Emerging Growth Company Segment Reporting [Abstract] Issuance cost on equity line paid in common stock Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Entity Central Index Key Entity Central Index Key IT equipment Technology Equipment [Member] License And Collaboration Revenues License And Collaboration Revenues [Member] License And Collaboration Revenues General and administrative General and Administrative Expense [Member] Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Accrued interest or penalties recorded related to uncertain tax positions Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] 2022 Stock Incentive Plan Two Thousand Twenty Two Stock Incentive Plan [Member] Two Thousand Twenty Two Stock Incentive Plan Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Juniper Pharmaceuticals, Inc. Juniper Pharmaceuticals, Inc. [Member] Juniper Pharmaceuticals, Inc. [Member] Potential future payment, percentage Royalty Agreement, Milestone Payments, Sales Based Potential Future Milestones Royalty Agreement, Milestone Payments, Sales Based Potential Future Milestones Schedule of Accounts Payable and Accrued Expenses Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Australian Taxation Office Australian Taxation Office [Member] Stockholders' Equity Equity [Text Block] Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Equity Component Equity Component [Domain] Preferred stock, par value (in usd per share) Preferred Stock, Par or Stated Value Per Share Segment Information Segment Reporting Disclosure [Text Block] Reconciliation of cash, cash equivalents and restricted cash to amounts reported in the consolidated balance sheets: Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract] Deferred grant funding Increase (Decrease) In Deferred Grant Funding Increase (Decrease) In Deferred Grant Funding Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Monthly payments under consulting agreement Consulting Agreement, Monthly Payments Consulting Agreement, Monthly Payments Payments to stockholders' representative in business combination Payments to Stockholders' Representative in Business Combination Payments to Stockholders' Representative in Business Combination Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Measurement Input, Risk Free Interest Rate Measurement Input, Risk Free Interest Rate [Member] Entity Shell Company Entity Shell Company Measurement Basis [Axis] Measurement Basis [Axis] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Credits recorded to research and development expense for costs related to award Research and Development Arrangement with Federal Government, Customer Funding to Offset Costs Incurred Revenue tier threshold, upper range limit Royalty Agreement, Revenue Tier Threshold, Incremental Amount Royalty Agreement, Revenue Tier Threshold, Incremental Amount Title Trading Arrangement, Individual Title Risks and Uncertainties Risks And Uncertainties [Policy Text Block] Risks and uncertainties Statement [Table] Statement [Table] Net operating loss carryforwards expiration year Operating Loss Carryforwards Expiration Period Operating loss carryforwards expiration period. Grant, ADARE-204 and ADARE-214 Grant, ADARE-204 and ADARE-214 [Member] Grant, ADARE-204 and ADARE-214 Fair Value, Measurement Frequency [Domain] Measurement Frequency [Domain] Counterparty Name [Axis] Counterparty Name [Axis] Asset acquisition, contingent consideration, current Asset Acquisition, Contingent Consideration, Current Asset Acquisition, Contingent Consideration, Current Unrecognized tax benefits Beginning uncertain tax benefits Ending uncertain tax benefits Unrecognized Tax Benefits City Area Code City Area Code Royalty Investment Financing Agreement Royalty Investment Financing Agreement [Member] Royalty Investment Financing Agreement Current Liabilities Liabilities, Current [Abstract] Auditor Location Auditor Location Other Effective Income Tax Rate Reconciliation, Tax Credit, Other, Percent State tax rate change Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent Change in control of company, termination for cause or for good reason Employment Agreement, Change in Control of Company, Termination for Cause or Good Reason Employment Agreement, Change in Control of Company, Termination for Cause or Good Reason Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Level 1 Fair Value, Inputs, Level 1 [Member] Foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Total current assets Assets, Current Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Accrued expenses Increase (Decrease) in Accrued Liabilities Options exercisable, ending (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Lincoln Park Capital Fund, LLC Lincoln Park Capital Fund, LLC [Member] Lincoln Park Capital Fund, LLC Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Weighted-average fair value of options granted (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Other Commitments [Axis] Other Commitments [Axis] Royalty revenue Royalty Revenue [Member] Royalty Revenue Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Measurement Input, Expected Term Measurement Input, Expected Term [Member] Total research and development indirect costs Research And Development Expense, Indirect Costs, Net Research And Development Expense, Indirect Costs, Net Income Taxes Income Tax Disclosure [Text Block] Basis of Presentation and Summary of Significant Accounting Policies Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Proceeds from research and development arrangement with federal government Proceeds From Research and Development Arrangement with Federal Government Proceeds From Research and Development Arrangement with Federal Government Equity [Abstract] Equity [Abstract] Contingent purchase price payments Royalty Agreement, Contingent Purchase Price Payments Royalty Agreement, Contingent Purchase Price Payments Accumulated deficit Accumulated deficit Retained Earnings (Accumulated Deficit) Issuance cost on equity paid in common stock Issuance Cost On Equity Paid In Common Stock Issuance Cost On Equity Paid In Common Stock Hard cap rate Royalty Agreement, Hard Cap, Percentage Royalty Agreement, Hard Cap, Percentage Research and Development Arrangement, Contract to Perform for Others, Type Research and Development Arrangement, Contract to Perform for Others, Type [Axis] General and administrative General and administrative General and Administrative Expense Issuable upon additional investment made number of securities called by warrants Class Of Warrant Or Right, Initial Royalty Warrant Issued Class Of Warrant Or Right, Initial Royalty Warrant Issued Organization, Consolidation and Presentation of Financial Statements [Abstract] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Equity Awards Adjustments Equity Awards Adjustments [Member] Weighted average interest rate Operating Lease, Weighted Average Discount Rate, Percent Total operating lease liabilities Operating Lease, Liability Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Contraceptive Product Grant Agreement Contraceptive Product Grant Agreement [Member] Contraceptive Product Grant Agreement Milestone payments rate Royalty Agreement, Milestone Payments, Percentage Royalty Agreement, Milestone Payments, Percentage Underlying Securities Award Underlying Securities Amount Exercised (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Exercised, Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Exercised, Weighted Average Grant Date Fair Value Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised Operating Loss Carryforwards [Line Items] Operating Loss Carryforwards [Line Items] Milestone revenue Milestone Revenue [Member] Milestone Revenue Amendment Flag Amendment Flag Aggregate Intrinsic Value * Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Aggregate Intrinsic Value Roll Forward Share based compensation arrangement by share based payment award options outstanding aggregate intrinsic value. Entity Registrant Name Entity Registrant Name Loss on disposal of property and equipment Gain (Loss) on Disposition of Property Plant Equipment Cash flows from operating activities Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Purchase And Registration Rights Agreement Purchase And Registration Rights Agreement [Member] Purchase And Registration Rights Agreement Direct program costs: Research And Development Expense, Direct Program Costs Research And Development Expense, Direct Program Costs DARE-LBT DARE-LBT [Member] DARE-LBT Research credit carryforwards expiration year Tax Credit Carryforward Expiration Period Tax credit carry forward expiration period. Fair Value as of Grant Date Award Grant Date Fair Value Subsequent Events [Abstract] Subsequent Events [Abstract] Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] Debt issuance cost Debt Issuance Costs, Net Options vested and expected to vest, ending Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Level 2 Fair Value, Inputs, Level 2 [Member] Sale of stock, number of shares issued in transaction Sale of stock, number of shares issued (in shares) Sale of Stock, Number of Shares Issued in Transaction Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Registration statement period Sale Of Stock, Registration Statement Period Sale Of Stock, Registration Statement Period Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Issuance of common stock, net of issuance costs Stock Issued During Period, Value, New Issues Entity Address, Postal Zip Code Entity Address, Postal Zip Code Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Schedule of Stock-Based Compensation Expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Principles of Consolidation Consolidation, Policy [Policy Text Block] Restatement Determination Date: Restatement Determination Date [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Title of 12(b) Security Title of 12(b) Security Concentration Risk Type [Axis] Concentration Risk Type [Axis] Common stock, $0.0001 par value, 240,000,000 shares authorized, 8,700,386 and 8,331,161 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively Common Stock, Value, Issued Audit Information [Abstract] Audit Information Document Financial Statement Error Correction [Flag] Document Financial Statement Error Correction [Flag] Ovaprene Ovaprene [Member] Ovaprene Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Income Tax Authority, Name [Domain] Income Tax Authority, Name [Domain] Forfeited or expired (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited And Expired, Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited And Expired, Weighted Average Grant Date Fair Value Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Upfront license fee paid Upfront License Fee, Amount Paid Upfront License Fee, Amount Paid State income tax, net of federal benefit Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Auditor Name Auditor Name Other Deferred Tax Assets, Other Amount due upon execution License And Services Agreement, Amount Payable Upon Execution License And Services Agreement, Amount Payable Upon Execution Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Concentration Risk [Line Items] Concentration Risk [Line Items] Preferred stock, $0.01 par value, 5,000,000 shares authorized; None issued and outstanding Preferred Stock, Value, Issued Net royalty payments rate Royalty Agreement, Net Royalty Payments, Percentage Royalty Agreement, Net Royalty Payments, Percentage Property and equipment, useful life Property, Plant and Equipment, Useful Life Number of Shares Underlying Warrants Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Research credit carryforward, subject To expiration Tax Credit Carry Forward, Subject To Expiration Tax Credit Carry Forward, Subject To Expiration Fair Value Measurement [Domain] Fair Value Measurement [Domain] Loss per common share - basic (in usd per share) Earnings Per Share, Basic Supplemental investment payment Royalty Agreement, Supplement Investment Payment Royalty Agreement, Supplement Investment Payment Accounts payable Increase (Decrease) in Accounts Payable Net proceeds from issuance of common stock Proceeds from Issuance of Common Stock Cash paid for measurement of operating lease liabilities Operating Lease, Payments Deposits Deposits Assets, Noncurrent Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Remaining obligation Contractual Obligation Grant, DARE-PTB2 Grant, DARE-PTB2 [Member] Grant, DARE-PTB2 Additions to property and equipment and reduction of deposits Capital Expenditures Incurred but Not yet Paid Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Outstanding, Weighed Average Remaining Life in Years Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms Net loss to common stockholders Net Income (Loss) Available to Common Stockholders, Basic Property and Equipment Property, Plant and Equipment, Policy [Policy Text Block] Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Hennepin License Agreement Hennepin License Agreement [Member] Hennepin License Agreement Stock, Class of Stock [Table] Stock, Class of Stock [Table] Grant Awards Grant Award [Text Block] Grant Award [Text Block] Total current liabilities Liabilities, Current Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] NICHD NICHD [Member] NICHD Weighted average number of common shares outstanding: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Total assets Assets Concentration of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Milestone payments, contingent amount, first commercial sale amount Milestone Payments, Contingent Amount, First Commercial Sale Amount Milestone Payments, Contingent Amount, First Commercial Sale Amount Schedule of Financial Assets and Liabilities Remeasured on a Recurring Basis Fair Value, Assets Measured on Recurring Basis [Table Text Block] Payments on note payable Repayments of Notes Payable Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Commitments and contingencies (Note 14) Commitments and Contingencies Stock-Based Compensation Share-Based Payment Arrangement [Policy Text Block] Phase I Segment Phase I Segment [Member] Phase I Segment Accrued royalties payable Accrued Royalties, Current Difference Between Provision (Benefit) for Income Taxes and the Amount Computed by Applying U.S. Federal Income Tax Rate Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Termination Date Trading Arrangement Termination Date Accounts payable and accrued expenses Accounts Payable and Accrued Liabilities [Member] Permanent differences Effective Income Tax Rate Reconciliation, Permanent Differences Effective income tax rate reconciliation, permanent differences. Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] Exercise Price (in usd per share) Exercise Price (in usd per share) Class of Warrant or Right, Exercise Price of Warrants or Rights 2026 Lessee, Operating Lease, Liability, to be Paid, Year Two Stock-based Compensation Share-Based Payment Arrangement [Text Block] Prepaid clinical expense Prepaid Clinical Expense, Current Prepaid Clinical Expense, Current Upon Achievement Of Specified Development And Regulatory Milestones Upon Achievement Of Specified Development And Regulatory Milestones [Member] Upon achievement of specified development and regulatory milestones. Entity Address, City or Town Entity Address, City or Town Leases Lessee, Leases [Policy Text Block] Phase 1 and Phase 1-ready clinical stage programs Phase 1 And Phase 1-Ready Clinical Stage Programs [Member] Phase 1 And Phase 1-Ready Clinical Stage Programs Debt Instrument [Axis] Debt Instrument [Axis] Summary of Stock Option Activity for 2015 Plan and Current Plan and Related Information Share-Based Payment Arrangement, Option, Activity [Table Text Block] Warrants Warrants [Member] Warrants Reverse stock split adjustment (in shares) Stock Issued During Period, Shares, Reverse Stock Splits Stock-based compensation expense Share-Based Payment Arrangement, Expense Net loss Net loss Net loss Net Income (Loss) Attributable to Parent Trading Arrangement: Trading Arrangement [Axis] Warrant, exercise price, decrease Warrant, Exercise Price, Decrease Federal Subaward Federal Subaward [Member] Federal Subaward Granted (in usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Defined contribution plan, employer matching contributions Defined Contribution Plan, Employer Discretionary Contribution Amount Business Acquisition [Axis] Business Acquisition [Axis] XACIATO XACIATO [Member] XACIATO Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Synthetic Synthetic [Member] Synthetic Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Entity File Number Entity File Number Estimated fair value of warrants Estimated Fair Value Of Warrants Recorded In Equity Estimated Fair Value Of Warrants Recorded In Equity Unremitted earnings Unremitted Earnings Unremitted earnings. Grant funding recognized during period Grant Funding Recognized During Period Grant Funding Recognized During Period Document Fiscal Year Focus Document Fiscal Year Focus Income Statement [Abstract] Income Statement [Abstract] Entity Address, Address Line One Entity Address, Address Line One Non-cash royalty revenue related to sale of future royalties Non-Cash Lease Expense Non-Cash Lease Expense Entity Address, Address Line Two Entity Address, Address Line Two July 2024 Financing July 2024 Financing [Member] July 2024 Financing Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Effect of exchange rate changes on cash and cash equivalents and restricted cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Other accruals Other Accrued Liabilities, Current Name Forgone Recovery, Individual Name Options exercisable, ending Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Foreign Income (Loss) from Continuing Operations before Income Taxes, Foreign Operating lease weighted average remaining lease term Operating Lease, Weighted Average Remaining Lease Term Document Period End Date Document Period End Date Sale of Stock [Axis] Sale of Stock [Axis] Term of related party agreement Related Party Transaction, Term Related Party Transaction, Term Contingent Consideration by Type [Axis] Contingent Consideration by Type [Axis] Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Total future minimum lease payments Lessee, Operating Lease, Liability, to be Paid Issuance of common stock from the exercise of warrants Issuance Of Common Stock From Exercise Of Warrants, Amount Issuance Of Common Stock From Exercise Of Warrants, Amount Expired (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Insider Trading Arrangements [Line Items] Prior year - reductions Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions Royalty payments Payments for Royalties Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount 2027 Lessee, Operating Lease, Liability, to be Paid, Year Three PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Forfeited or expired (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations Schedule of Common Stock Reserved for Future Issuance Schedule Of Common Stock Reserved For Future Issuance [Table Text Block] Schedule of common stock reserved for future issuance Warrants and rights outstanding (in shares) Relative fair value of Initial Royalty Warrant Warrants and Rights Outstanding Adjustment to Compensation: Adjustment to Compensation [Axis] Reclassification of Prior Year Presentation Reclassification, Comparability Adjustment [Policy Text Block] Restricted cash included in other non-current assets Restricted Cash and Cash Equivalents, Noncurrent Document Transition Report Document Transition Report Reportable Segment Reportable Segment [Member] Reportable Segment Schedule of Reconciliation of the Beginning and Ending Amount of Uncertain Tax Benefits Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block] Customer [Domain] Customer [Domain] Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Current Reporting Status Entity Current Reporting Status ADVA Tec Agreement A D V A Tec Agreement [Member] ADVA Tec agreement. Accumulated Deficit Retained Earnings [Member] Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Douglas License Agreement Douglas License Agreement [Member] Douglas License Agreement Income Tax Authority, Name [Axis] Income Tax Authority, Name [Axis] Effective annual interest rate Royalty Agreement, Effective Annual Interest Rate, Percentage Royalty Agreement, Effective Annual Interest Rate, Percentage Indirect costs: Research And Development Indirect Costs [Abstract] Research And Development Indirect Costs Related Party [Axis] Related and Nonrelated Parties [Axis] Basic (in shares) Weighted Average Number of Shares Outstanding, Basic Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Reverse Stock Split Stockholders' Equity, Policy [Policy Text Block] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Executive Category: Executive Category [Axis] Name Awards Close in Time to MNPI Disclosures, Individual Name Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Organon Organon [Member] Organon Summary of Components of Loss from Continuing Operations Before Provision for Income Taxes Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Entity Filer Category Entity Filer Category Payment of additional consideration in business combination Payment of Additional Consideration in Business Combination Payment of Additional Consideration in Business Combination Statement of Income Location, Balance [Domain] Statement of Income Location, Balance [Domain] Operating loss carryforward, subject to expiration Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration Company Selected Measure Name Company Selected Measure Name